Despite the similar average tumor volume presented by mice treated with Nanovaccine + TIME‐targeted NP, Nanovaccine_siTGF‐β1 + TIME‐targeted NP, or Nanovaccine_siTGF‐β1 + TIME‐targeted NP + Pexidartinib, the downregulation of TGF‐β1 expression in tumors was only confirmed when the Nanovaccine_siTGF‐β1 was administered subcutaneously (s.c.)in combination with the TIME‐targeted NP, with or without pexidartinib (Figure 3F,G). Here, TGFB1 is linked to neoplasm.